{"title":"Roche strikes $5.3 billion amylin deal","authors":"","doi":"10.1038/s41587-025-02657-1","DOIUrl":null,"url":null,"abstract":"<p>Roche is gaining access to petrelintide, a potentially best-in-class amylin analog, paying Copenhagen-based Zealand Pharma $1.65 billion up front and up to $5.3 billion in total to co-develop the weight-loss molecule. Petrelintide is a long-acting acylated version of the pancreatic peptide amylin. Several companies are pursuing amylin analogs as antiobesity agents because they work by increasing satiety. Their advantage over glucagon-like peptide-1 (GLP-1) agonists such as Wegovy (semaglutide) is that they cause less nausea and vomiting, and may lead to less muscle loss, according to rodent studies. Amylin analogs mimic the natural pancreatic peptide amylin, which is secreted with insulin by the pancreas, whereas GLP-1 agonists mimic incretin hormones, produced in the gut to suppress appetite.</p><p>So far, in an ongoing phase 2 trial, participants receiving petrelintide, given by once-weekly injection, lost only 7% more weight than people receiving placebo. A 15–20% weight loss, similar to that of GLP-1 agonists, is the aim for future trials.</p>","PeriodicalId":19084,"journal":{"name":"Nature biotechnology","volume":"16 1","pages":""},"PeriodicalIF":33.1000,"publicationDate":"2025-04-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature biotechnology","FirstCategoryId":"5","ListUrlMain":"https://doi.org/10.1038/s41587-025-02657-1","RegionNum":1,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOTECHNOLOGY & APPLIED MICROBIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Roche is gaining access to petrelintide, a potentially best-in-class amylin analog, paying Copenhagen-based Zealand Pharma $1.65 billion up front and up to $5.3 billion in total to co-develop the weight-loss molecule. Petrelintide is a long-acting acylated version of the pancreatic peptide amylin. Several companies are pursuing amylin analogs as antiobesity agents because they work by increasing satiety. Their advantage over glucagon-like peptide-1 (GLP-1) agonists such as Wegovy (semaglutide) is that they cause less nausea and vomiting, and may lead to less muscle loss, according to rodent studies. Amylin analogs mimic the natural pancreatic peptide amylin, which is secreted with insulin by the pancreas, whereas GLP-1 agonists mimic incretin hormones, produced in the gut to suppress appetite.
So far, in an ongoing phase 2 trial, participants receiving petrelintide, given by once-weekly injection, lost only 7% more weight than people receiving placebo. A 15–20% weight loss, similar to that of GLP-1 agonists, is the aim for future trials.
期刊介绍：
Nature Biotechnology is a monthly journal that focuses on the science and business of biotechnology. It covers a wide range of topics including technology/methodology advancements in the biological, biomedical, agricultural, and environmental sciences. The journal also explores the commercial, political, ethical, legal, and societal aspects of this research.
The journal serves researchers by providing peer-reviewed research papers in the field of biotechnology. It also serves the business community by delivering news about research developments. This approach ensures that both the scientific and business communities are well-informed and able to stay up-to-date on the latest advancements and opportunities in the field.
Some key areas of interest in which the journal actively seeks research papers include molecular engineering of nucleic acids and proteins, molecular therapy, large-scale biology, computational biology, regenerative medicine, imaging technology, analytical biotechnology, applied immunology, food and agricultural biotechnology, and environmental biotechnology.
In summary, Nature Biotechnology is a comprehensive journal that covers both the scientific and business aspects of biotechnology. It strives to provide researchers with valuable research papers and news while also delivering important scientific advancements to the business community.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
